center of the well was scratched with a new 1ml pipette tip, and gently washed twice with medium to remove the detached cells. The well was replenished with fresh medium containing PG545 and gemcitabine. The cells were grown for additional 48 hours and washed twice with 1 × PBS, then fixed and stained with Diff-Quick staining solution (Sysmex, Japan). The stained cells photographed with a camera mounted on a microscope (AXIO observer A1, Zeiss, Germany). The wound healing area was measured with the ImageJ, image processing program.
Establishment of gemcitabine resistant pancreatic cancer cell lines
Gemcitabine resistant AsPC-1 and BxPC-3 cells (AsPC-1/GR and BxPC-3/GR) were derived from each original parental cell lines by continuous exposure to gemcitabine (Sigma-Aldrich, USA) during several months in increasing concentrations up to 100 nM. The resistant cells were continuously maintained in a medium containing 50 nM of gemcitabine prior to each experiment.
Animal groups and tumor monitoring using animal imaging system
Tumor volumes were measured weekly by the bioluminescence IVIS Imaging System 200 using a cryogenically cooled imaging system coupled to a data acquisition computer running Living Image software (Xenogen Corp., Alameda, CA). Before imaging, animals were anesthetized in an acrylic chamber with 2.5% isoflurane/air mixture and injected i.p. with 40 mg/mL d-luciferin potassium salt in PBS at a dose of 150 mg/kg body weight. After 10 min of incubation with luciferin, mice were placed in a right lateral decubitus position and a digital grayscale animal image was acquired followed by acquisition and overlay of a pseudo color image. Signal intensity was quantified as the sum of all detected photons within the region of interest per second. Mice were imaged on days 0, 7, 14, 21, 24, and 31 of treatment. Treatment was continued for 4 weeks and all mice were sacrificed 1 week later. Primary tumors in the pancreas were excised and the final tumor volume (V) was measured as V = 2 / 3πr 3 , where r is the mean of the three dimensions (length, width, and depth). Half of the tumor tissue was formalin fixed and paraffin embedded for immunohistochemistry and routine H&E staining. The other half was snap frozen in liquid nitrogen and stored at −80°C for immunoblotting.
Tumor sections for Immunohistochemistry
Tumor sections were cooled on bench top for 30 min, treated with 3% hydrogen peroxide in methanol for 10 min, and blocked with 6% horse serum for 30min at room temperature. Sections were then incubated with the primary antibody at 4°C overnight in humidity chamber. Sections were washed in PBST and incubated with secondary antibody (biotinylated goat anti-rabbit (1:150, Vector Laboratories, Burlingame, CA, USA) or biotinylated rabbit anti-rat IgG (1:150, Abcam, Boston, MA, USA) for 40min in humidity chamber. After further washes, the antibodies were detected with the Vector ABC complex/horseradish peroxidase (HRP) kit (Vector Laboratories, Burlingame, CA, USA), and color developed with 3,3′-diaminobenzidine tetrahydrochloride. For semiquantitation, ten photomicrographs (200×) were taken with a CCD camera, avoiding gross necrotic areas. The inhibition of AsPC-1 and Panc-1 cell proliferation by PG545 was measured using the BrdU assay after 24 h exposed to PG545 and Wnt3a (50 ng/ml). AsPC-1 cells were treated with indicated concentrations of PG545 and gemcitabine for 48h. Western blot analysis was performed using antibodies against caspase 8 and β-actin. Treatment details given in Materials and Methods. Group1 was given PBS (100 μL, twice weekly by i.p.), group2 was given PG545 (200 mg/kg, twice weekly by i.p. injection), group3 was given gemcitabine (25 mg/kg, twice weekly by i.p. injection) and group4 was given PG545 (10 mg/kg) and gemcitabine (12.5 mg/kg) twice weekly by i.p. injection. 
